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Atypical antipsychotics: Clinical experience:
1. Factors warranting switch
2. My experience with XR
3. Are there differences amongst atypical
4. How to maximize clinical advantage 
Despite lack 
of clarity in 
selection, 
90% times 
each clinician 
gets it right.
Quetiapine Optimization: Case report
 Mrs B, 48 Years , Married
 Chronic  schizophrenia with 
Chronic unremitted 
alcoholism, and chronic 
suicidality , 
 H/O 4 major attempt, 
 F/U regular, > 20 Admissions, 
 on Quetiapine 525 IR + 
Olanzapine 20 mg.
 Readmitted, APE,    
 Day I – QUT.IR, 100 mg QHS, 
syncope attack, two episodes,
 Ref. General hospital, Cause-
Unknown,
 Re-evaluated: opinion ‘she 
has this  problem since the 
age of 20,
 no diagnosis was made,  
 Reassessed for diagnosis and 
care plan
Schizophrenia with alcoholism & Suicidality
Case Report..Conti.
 Target: psychosis, suicide, alcoholism, Involuntary admission
 Discontinued passes, Family Meeting.
 Discontinued olanzapine,
 Plan: Increase quetiapine to 800 mg/day gradually & monitor
 Once escalation was complete, we switch to XR 800 mg Q Super
 Increased 5 mg a day, i.e. 25 mg every 5th day,
 Vitals monitored, psychosocial therapy continued.
 800 mg in  10 weeks,  No further syncope
 Mental state: Remarkable change, ‘Never felt like 
this’,                     No suicidality.
 Discharged under care of her outpatient psychiatrist
Why do we need to switch?
 Lack of efficacy
 Acute relapse
 Side effects
– Intolerability
– Burden 
 Failed
 optimization
 adjunct treatment
 ‘Patients-Choice’
Fundamental Process in switching APD
1. Establish a causal attribution   
2. Understand course of side effect
3. Understand potential risk of individual patient
4. Be aware of the SE profile of other possible 
antipsychotics
5. Calculate SE risk of switch
6. Calculate efficacy risk of switching
Symptoms warranting a switch 
• Persistent 
Positive 
symptoms
• Persistent 
Negative 
symptoms
• Persistent 
Cognitive 
symptoms
• Persistent 
affective 
symptoms
Persistent poor 
Social 
Functioning
Weiden PJ,2006, Psychopharm
Persistent EPS Galactorrhea & Amenorrhea
Gynaecomastia & 
Impotence in men
Lambert TJ. Switching antipsychotic therapy: what to expect and clinical 
strategies for improving therapeutic outcomes. J Clin Psychiatry 
2007;68(suppl 6):10–13  
Switching strategies for antipsychotic 
medication 
Clinical Consequences of switching
NOT so Good 
experience
Withdrawal 
symptoms 
Secondary 
symptoms ( 
anxiety-insomnia)
Persisting side 
effects of prior 
APD
New psychiatric 
symptoms
Side effects of 
newer APD
Break-through 
Psychosis
Fall, giddiness, fai
nting, 
Emergency 
situation 
( Seizure, low 
blood 
count, Cardiac 
event, Steven-
Johnston)
Good 
experience

Pharmacology of Atypical Antipsychotics
In vitro findings may not correlate with clinical results.
Zorn SH et al. In: Interactive Monoaminergic Brain Disorders (Palomo T, ed.), 1999, p.377-393.
Schmidt AW et al. Eur J Pharmacol 2001;425:197-201.
The mechanism of action of second-
generation neuroleptics (risperidone)
How long to wait for response
• An average of 3 weeks  
• Sometimes  as long as 3 months  ( clozapine )    
• Variability in medical decisions.
• Early responders
• Late responders
• >50% reduction in PANSS over 12 weeks
• Drug trials 2 , 4, 12 weeks
• Sustained response Vs lost response in long-term 
Response Remission Recovery 
• Considerable divergence of 
expert opinion
• One survey of experts 
indicated that a period of 2.6 
to 5.5 weeks was required.
• Lack of minimal response 
after 1 or 2 weeks is a 
powerful Predictor of 
subsequent poor response   6 weeks     12 weeks      ???
1. Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: 
definition, prevalence and predictors. Expert Opin Pharmacother. 2008 Aug;9(12):2027-38. 

Criteria's for Response 
Poor Social functioning also a criteria for 
non-response 1
Predicting response: early response 
( 2 wks) correlates to long-term efficacy . 
Leucht S, Busch R, Kissling W, Kane JM.  Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin
Psychiatry. 2007 Mar;68(3):352-60 
Partial Adherence in Schizophrenia Begins 
Early and Prevalence Increases Over Time
Time From Discharge
50
75
1. Velligan DI, et al. Psychiatric Services. 2003;54:665-667. 
2. Weiden PJ, Zygmunt A. J Prac Psych Behav Health. 1997;March:106-110.
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Dosing Frequency & Compliance
Me
an
 C
om
pl
ian
ce
Switch & persistent symptoms
 Positive symptoms
 Negative symptoms
 Cognitive
 Suicide
 Violence
 Substance abuse
 Poor social functioning
HALD, QUET, OLANZ
• RISP, QUET, CLOZ, ARIP, PALP
• RISP, ZPS, CLOZ, ARIP
• Clozapine
• Clozapine
• Clozapine
• Clozapine
Benefits of switching 
Switch to Quetiapine
From Olanzapine 
 Reduced 
– Akathesia
– Dyslipidemea
– EPS
– Prolactin
– Weight 
From Ziprasidone
 Reduced
– Akathesia
– EPS
– insomnia
Experience with Quetiapine XR
Clinical details
 N = 40 
 Minimum Duration:  6 Weeks
 Maximum duration: 12 months
 Continued Treatment: 30
 Currently under follow up:25
 Discontinuation:10
– Side effect: 3
– Loss of effect:3
– Intolerability:4
 Efficacy : excellent 
 Good outcome: 18/25 (72%)
 Inadequate response: 2/25 
(12%)
 Good Tolerability: 32/40(82%)
 Significant side effects: 5/40 
(12.5%)
– Increased sedation
– Dryness of mouth
– Rebound Insomnia
– Somnolence 
Dosing ( N=33)
 50 mg: 04
 200 mg: 02
 300 mg: 07
 500 mg: 05
 600 mg: 03
 800 mg: 06
 1000 mg: 01
 1200 mg: 03
Diagnostic category
• Acute psychosis
• Schizophrenia (paranoid, 
Undifferentiated)
• Bipolar Affective Disorder ( Manic 
episode)
• Bipolar depression
• Bipolar spectrum disorder
• Schizoaffective disorder
• Anxiety-insomnia
Symptom-syndrome response
Good :  Behavior, Mood & affect, 
Sleep, Positive symptoms, 
Disorganization, Negative 
symptoms, Affective symptom, 
Depressed mood, Manic and 
hypo manic, Irritability, 
Insomnia, Suicidality, 
Concentration 
 Limited efficacy: Thought 
disorders , Delusions, First 
rank symptoms,  Cognitive 
function , Residual feature, 
motivation
Merits
 Rapid titration
 Once a day dosing
 Easy administration
 Increased compliance
 Day time alertness
 Rapid response for 
behavior and mood 
symptoms
 Effect of suicidality
Why XR?
 Historically: 
 From Rapid Neuroleptization-
to- Rapid Tranquilization in a 
range of indications
 Chlorpromazine IM/PO
 High dose fast escalation of 
Haloperidol IM/IV
 Rapid escalation of Lithium PO
 Rapid and fast valproic acid 
IM/PO
 Rapid Benzodiazepine IM/IV/PO
 Bolus Opiates IM
 No clinical benefit
 High risk of side effect
 CNS depression
 Acute cardiac event
 Delirium
 Movement disorder
 NMS
Comprehensive therapy 
XR Quetiapine
1.Only oral
2. Less life-threatening side effects
3. No seizure or cardiac event
4. 800 mg day 2
Vulnerable population & Atypical 
antipsychotics
 Children
 Elderly
 Alzheimer's
 Dementia 
 Neurological illness
 Preexisting cardiac 
illness 
 Arrhythmia
 Seizures
 Sudden death
 Increased Mortality in 
AD 
 Stroke in elderly
Is switch 
clinically effective?
Switch studies
1. Switch to XR: 68% achieved clinical benefit
2. Rosenheck RA et al, 2009, switch from Olanzapine to 
quetiapine: Vs. Continued on Olanzapine: No added benefit but 
High weight gain in Olanzapine
3. Debert W, et al 2008, Olanzapine Vs Switch to Quetiapine: No 
difference in Relapse Rate at 200 days 
4. CATIE Switcher’s Vs Stayer’s : No difference in outcome at 18 
Months within 5 groups, High weight gain for Olanzapine, 2009
5. Switch to Quetiapine Vs Paliperidone: No difference in Long-
term, extension phase, 2009
Are there differences amongst atypical
1. No differences amongst SGA except Clozapine
2. Non-significant differences on axis & domains of 
schizophrenia
3. Choice within SGA remains mainly guided by side 
effect profile
The new  ‘statistics’
Meta analysis
Are there differences 
which are not seen?
OR
Are the differences not there, 
& we are trying to ‘fish’?
All  Atypicals are SDA
Differences are expected on efficacy & 
side effect
Outcome 
degree of 
improvement
Symptoms & 
Function
Various 
domains 
Skills Time line , earliest
Domains
Positive 
Negative 
Affectiv
e 
Cognitive
Social 
functioning 
New skills
QOL
ADL
Side 
Effects
EPS
Vitals
Sedation
WeightMetabolic 
Cardiac
Blood 
count 
seizure
Differences are expected on efficacy & 
side effect
Symptom 
Remission
Social Recovery
Absence 
of side 
effects
Parameters of monitoring 
CATIE – Phase 3, Symptom response
No difference across all groups, However individual 
variations
Drugs ARIP CLOZ COMB FLU-D OLAN PERP QUET RISP ZIPR
P-
value
PANSS 
– 3 
months
0.506 0.002
✓
0.002 0.005
✓
0.002
✓
0.084 0.013 0.044 0.045 0.832
✖
PANSS
-6
<0.00
1
✔✔
0.006
<0.00
1
✔
0.43 0.003
✔
0.018 0.100 0.009 0.371 0.515
✖
• Outcome of switch is  dependent upon
– Medication switched to, Medication switched 
from.  
Stroup T et al, Schizophrenia Research 107 (2009) 1-12
Cognition, atypical antipsyhotics & 
Schizophrenia
 Commonest manifestation
 Deficit leads to functional & social decline
 Improvement mediates social recovery
 Number of Studies attempted, CATIE, CAFÉ, biases ? 
 General impression – SGA – beneficial
 Benefit is small in effect size
 Better than FGA
 No difference across different molecules
“our hope from atypical antipsyhcotics for
cognitive enhancement is lost… we may have 
to look somewhere else for this effect..”
M.Green, Editorial in AJP, 2007
Cognition & Atypicals: General Conclusions 
There is a moderate procognitive effect for 
early psychosis, poorly correlated with 
symptoms & all SGA have similar results,      
at 2, 6, 18 months
– June 2009, AJP
Opinion : Academics 
FGA & SGA: Broad spectrum
Case report. AB 52 years, Clozapine
 Chronic psychosis, living in a group home, no family 
support, smoker, multiple hospitalization, resistant  
illness, low functioning,
 4th hospitalization agreed for clozapine, 
 Showed good response to 300 mg/day;   remission for 
12 months
 Developed low count, low ANC admitted again for 
monitoring  
 Mild behavioral problem after 1 week.
• Blood count improved i  2 weeks. Antipsychotics- free 
state  for 3 weeks
• Re-challenging clozapine??
• Started Pimozide 4 mg, increased to 12 mg per day, 
• Discharged after 4 weeks, Regular follow up for 18 
months, 
• Go d remission, ADL,  good QOL, No major concerns,
EPS across AAPD at 6 month outcome
Are there differences in side effect profile 
Stroup T et al, Schizophrenia Research 107 (2009) 1-12
TD: High in Geriatric Population with 
SGA
Akathesia 
 High dose
 High potency SGA
 Combination of SGA
 SGA with other 
psychotropics
 Bipolar depression
 Palliative care setting
 Comorbid SUD
EPSE, Akathesia Prevalence 
SGA
Clozapine 35% (45%)
Risperidone 25-27% 
Olanzapine 3%-6%
Quetiapine V 
Placebo
12.9 V 13.1% 
(21.4% with 
Lithium, DVS)
Aripiprazole 21% with ADD, 
RR 0.39
Drug Weight Gain Risk for 
Diabetes
Worsening 
Lipid Profile
Clozapine (Clozaril) +++ ++ ++
Olanzapine (Zyprexa) +++ ++ ++
Risperidone (Risperdal)
Paliperidone (Invega)
++ +/- +/-
Quetiapine (Seroquel) ++ +/- +
Aripiprazole* (Abilify) +/- - -
Ziprasidone* (Geodon) +/- - -
Antipsychotic 
Drugs and Obesity and Diabetes 1
+ = increase effect; - = no effect; D = discrepant, results. *Newer drugs with limited long-term data, 1. 
ADA/APA Consensus Conference 
Weight Gain and AAPD 
Stroup T et al, Schizophrenia Research 107 (2009) 1-12
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One subject likely to gain >7% weight out of 
Early Weight gain persists 
Short (N=1717, 4-12 wks) & Long-term (N=1649, 52 wks), 
Bruce,P et al, Weight effects associated with antipsychotics: A comparative database analysis, 
Schizophrenia research 110 (2009) 103-110
Diabetes and Antipsychotics
 Schizophrenia & Diabetes Mellitus: 
– Many studies shown ↑ risk in schizophrenia:
• IGT, Insulin resistance
• Type 2 Diabetes mellitus
– 10% Schizophrenia > 6–8% general population
– Studies over several decades, predating both typical & 
atypical neuroleptics
 RCT Data – Summary:
– Results:
– 9% of all patients Rx with antipsyhotics developed new DM
– clozapine, olanzapine, haloperidol ↑ FBS
– clozapine, olanzapine ↑ Fasting Cholesterol
– No correlation between weight gain and FBS in this study
Do Atypical antipsychotics cause DM?
 Basic Science
• Normal insulin secretion, ↓ insulin sensitivity with ↑ weight
 1 flawed RCT, Cohort Studies, Case Reports/Studies
– 9% of patients Rx with any antipsyhotic developed new DM
– clozapine, olanzapine, haloperidol ↑ FBS
– clozapine, olanzapine ↑ Fasting Cholesterol
– Less DM risk with Risperidone?
 Can DM be  predicted or prevented?
– Risk factors for T2DM
• Obese, older, ethnic groups, FHx DM, etc.
– Risk factors for DKA
• Thin, younger, female?
Metabolic profiles of SGA in early psychosis: 
Findings from the CAFE study.2009
Patel JK, Buckley PF  Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study.
Schizophr Res. 2009 Jun;111(1-3):9-16. Epub 2009  
Cardio-metabolic Disease Risk Factor 
Schizophrenia Bipolar 
Disorder
Modifiable risk 
factor
Estimated 
Prevalence of 
risk factor (%)
Relative Risk Estimated 
Prevalence of 
risk factor (%)
Obesity 45-55 1.5-2 x 26
Smoking 50-80 2-3 x 55
Diabetes 10-14 2 x 10
Hypertension >18 15
Dyslipidemia Up to 5 x
Public Health measures for metabolic 
side effects
 Meta analysis (N=35K, 152 mortality study):                                    2 
fold risk of premature death.
 CVD leading cause of death in SMI: US public sector data.
 8.3X (5x Female) increase in death 1991-1995, CVD mortality in 
‘first hospitalization’.
 Varying effect on FGA & SGA
 Adiposity dependent effect
 Insulin resistance.
 Risk of dyslipidemia, obesity, weight gain, raised blood sugar 
Newcomer J.W,  J. Clinical psychiatry, 2007;68 [suppl.4] : 8-13
Atypical antipsychotics &  Comorbidity
A UK audit of screening for the metabolic side effects 
of antipsychotics in community patients
Under detected metabolic Side effects: 
UK sample  
1
1
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known missed
Sedation – related Discontinuation
 It is every day -affair
Weiden PJ.J.Clin Psychiatry 2007;68 [suppl 1]:12-19
Prolactin and antipsychotics
Stroup T et al, Schizophrenia Research 107 (2009) 1-12
Factors compromising outcome and 
efficacy in treatment of schizophrenia
 Axis I – Psychiatric co morbidity (>20%), 
SUD (>50%)
 Axis II – Learning disability,      (5%) 
Personality Disorder   (10-15%)
 Axis III – Physical comorbidity                   (30-40%), 
Treatment emergent symptoms ( >50%)
 Axis IV – Rarely absent
 Axis V - Functioning – consider as outcome criteria 
Sketch model of barriers in Care in 
Schizophrenia  
Patient & their 
Personalities 
Mental illness & 
illness-related 
disability-stress
Treatment –
related factors
Family related 
factors
Organizational & 
mental health 
system barriers
Need for Change in Strategy 
 Care plan
 Continuity  
 Rapport  
 Multi-factorial  
 Goals
 Achievable objectives
 Assessment 
 Follow up
1. Treatment of side effects  
2. Use of 
1. ADJUNCT
2. COMBINATION APD
3. Potentiation of APD
4. For added efficacy
3. Treatment of psychiatric 
comorbidities
1. Anxiety –phobia, 
dysthymia, OCD 
Maximizing Outcome: Strategies  
Clinical options: need for innovation
 Typical antipsychotics
 Atypical antipsychotics
 SGA + BZ &/ ADD + &/ 
Mood stabilizers
 Combination of  FGA + 
SGA
 Combination of 2 SGA
 Clozapine
 Clozapine + SGA
 Clozapine + FGA+ SGA
 ECT
 Clozapine + ECT
 TMS
Varying level of evidence  
Psychosocial therapies are part of 
comprehensive management 
 Various Psychosocial
therapies
 Family therapy
 CBT in Psychosis
 Cognitive remediation
Experiments
Add-on Risperidone & Clozapine to haloperidol non-responders. 
Randomized Open level. N=90) 
Shrivastava,A et al. American psychiatric Association Annual Meeting,Abtracts 2000
Schizophrenia has substantially high risk of  
Comorbidity (Vs. population) 
: OR: 4.6
1.Hunt GE et al, Schizphr.Res, 2002; 64: 253-264,     2.Carney et al 2006 J.Gen.Intern.Med
P<0.001
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Nonadharence in schizophrenia and Comorbid Substance abuse. 1
High rates of psychiatric and other medical conditions. More than 75% 2
Cannabis 
Explanation for close relationship between 
Psychosis &  cannabis is still unclear. 
Suicide 
 10-13% die due to suicide.
 50% ideation, 25% attempters- sometime in lifetime
 High rate of suicide with in 1-2 months of discharge 1
 SMR increased 48.9 – fold in post discharge period 2
 FES- 15% attempted prior to entry & 8.7% during the treatment ( 
Comorbidity, h/o past attempt, Greater insight, low baseline 
functioning- predictors) 3
1. Hunt, I
2.Ajdacic-Gross V,In-patient suicide - a 13-year assessment. Acta Psychiatr Scand. 2009
3.Robinson J Prevalence and predictors of suicide attempt in an incidence cohort of 661 young people with first-episode
psychosis., Aust N Z J Psychiatry. 2009 Feb;43(2):149-57
High suicide in recently discharged patients
40%
42%
44%
46%
48%
43%
47%
Died within one month Died before FIRST F/U
 History of self-harm, 
 symptoms at last contact
 Initiated own discharge
 Missed last appointment  
 Detained for compulsory 
treatment: low risk  
N=238, Death by suicide within 3 month of discharge
Final message 
 Switching should  NOT be  the priority .
 It does not give any superiority in terms of 
efficacy amongst SGA except clozapine.
 Outcome of switch depends upon both the 
previous and the new molecule.
 The first clinical option should be optimization 
of dose, schedule, education & non-drug 
therapies.
It should be opte  only if clinical c nditions 
are compelling.
 Whenever switch, due consideration should be 
given to all denominators of its outcome.
 Not to compromise efficacy. 
Not to pers st with side effects.
